Achema middle east

RBI seeks clarity on FII investment in pharmaceutical sector

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Smart Laboratories and the Rise of Connected Pharma Equipment Ecosystems

Connected equipment ecosystems revolutionize pharmaceutical operations by integrating AI-driven analytics, digital twins, and seamless middleware to enhance visibility, collaboration, and decision-making across the value chain.

Maximizing Portfolio Returns During Late-Stage Drug Development

Optimize late-stage pharmaceutical assets through strategic investment planning, risk management, and indication prioritization. Maximize R&D return on investment during the highest-stakes phase of drug development.
- Advertisement -

The Reserve Bank of India (RBI) has sought clarity on whether foreign portfolio investments can be allowed in existing companies without government approval, putting the spotlight back on a sector that has been the subject of much debate and policy change with respect to overseas investment.

 

The current policy for the pharma sector allows foreign direct investment (FDI) up to 100% through the automatic route in greenfield units, but investment in existing companies needs the approval of the Foreign Investment Promotion Board (FIPB).

The central bank has written to the finance ministry seeking to know the regime for foreign portfolio investment in listed Indian pharmaceutical companies – whether it can be allowed without prior FIPB approval. “The RBI basically wants clarity since there is a new regime in place for the pharma sector,” said a finance ministry official who didn’t want to be named. The ministry has initiated discussions with the Department of Industrial Policy and Promotion (DIPP), which has administrative charge of the FDI policy, to take a final call on the issue.

The distinction between greenfield projects and brownfield ones was introduced last year amid concern that Indians will be denied cheap medicines if multinationals continued to acquire control of local drug firms.

Foreign direct investment in the sector now attracts certain special conditions. These include having to manufacture and make available essential drugs for five years after the acquisition and to increase R&D expenditure by 5% for diseases prevalent in India.

Under the current rules, portfolio investment is allowed up to 24% in a listed company. It can be further raised to the sectoral limit through a board resolution and a special resolution of the shareholders. Individual portfolio investors can hold up to 10% in a company.

Experts do not see the need for FIPB approval for portfolio investments by foreign institutional investors. “FIPB approval requirements and FDI policy conditionalities should not apply to FII investments under the portfolio investment scheme. It would otherwise require specific amendment in FEMA (Foreign Exchange Management Act) regulations,” said Akash Gupt, executive director, PwC.

The RBI wants to play safe on the issue of foreign investment in the sector that has already seen intense debate within the government.

A similar issue about adhering to sectoral conditions had also cropped up with respect to portfolio investment in multi-brand retail. A proposal by Future Retail to raise portfolio investment in the venture was directed by the RBI to FIPB and then to DIPP. It is still pending approval. An official said the issue is expected to get resolved once the Arvind Mayaram panel on aligning the definition of FDI and portfolio investment gives its report.

Latest stories

Related stories

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Smart Laboratories and the Rise of Connected Pharma Equipment Ecosystems

Connected equipment ecosystems revolutionize pharmaceutical operations by integrating AI-driven analytics, digital twins, and seamless middleware to enhance visibility, collaboration, and decision-making across the value chain.

Maximizing Portfolio Returns During Late-Stage Drug Development

Optimize late-stage pharmaceutical assets through strategic investment planning, risk management, and indication prioritization. Maximize R&D return on investment during the highest-stakes phase of drug development.

India Outpaces Global Average With 2026 Medical Trend at 11.5 Percent: Aon Reports

Cardiovascular diseases, gastrointestinal conditions and cancer are top medical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »